Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Sickle Cell Anemia
Interventions: Prasugrel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 11 more

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 14,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more

Conditions: Type 2 Diabetes Mellitus
Interventions: placebo, Exenatide LAR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 7
States / cities: Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more

Conditions: Sickle Cell Anemia Crisis
Interventions: Acetaminophen, Normal saline; Drug
Lead sponsor: Newark Beth Israel Medical Center; Other
Eligibility: 4 Years to 16 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Newark, New York

Conditions: Prediabetes, Type 2 Diabetes
Interventions: Metformin, Liraglutide, Glargine, Placebo; Drug
Lead sponsor: RISE Study Group; Network
Eligibility: 20 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington

Conditions: Pain
Interventions: Magnesium, Normal saline; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 4 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions: Active Dronabinol, Placebo, Active Ethanol; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: Pioglitazone; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Overweight and Obesity
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution; Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety
Interventions: Randomized Midazolam, Placebo, Local Anesthesia, Prospective Midazolam; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sickle Cell Disease
Interventions: Voxelotor, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Autism Spectrum Disorder
Interventions: Placebo, RO5285119; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 45
States / cities: Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 26
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Obesity
Interventions: Freeze-dried whole-grape powder; Dietary Supplement
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Denton, Texas

Conditions: Coronary Heart Disease
Interventions: Placebo, dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Mild Concussion, Brain Concussion, Cerebral Concussion
Interventions: Docosahexaenoic acid, Placebo; Dietary Supplement · Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Healthy Volunteers
Interventions: ABBV-243, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Inflammation
Interventions: Breakfast meal with placebo powder, Breakfast meal with 2 serving equivalents of blueberries, Breakfast meal with 4 serving equivalents of blueberries; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Davis, California

Conditions: Necrotizing Enterocolitis
Interventions: hydrocortisone, placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 0 Days to 6 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Search by objective public record fields.

Prasugrel Versus Placebo in Adult Sickle Cell Disease

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?

RISE Adult Medication Study

Magnesium vs Placebo for Tonsillectomy

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Effect of Whole-grape Powder on Body Composition, Fat and Bone Serum Biomarkers in Postmenopausal Women

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

The Effects of Antioxidants in Blueberry Powder on Inflammation Induced by a Single High Fat Meal.

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants